A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

NCT01051531 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

546

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Paliperidone palmitate

Sponsor

Janssen Research & Development, LLC